Targeting the Ang-(1-7)/Mas receptor axis represents a compelling therapeutic strategy with the potential to reverse lung damage, restore pulmonary function, and arrest disease progression in PE and COPD. The gene discussed is ANG; the disease is chronic obstructive pulmonary disease.